Glucosaminylmuramyldipeptide - GMDP: effect on mucosal immunity (on the issue of immunotherapy and immunoprophylaxis)

Abstract

The analysis of the clinical application effectiveness of the drug Limpid® (the substance is glucosaminylmuramyldipeptide - GMDP), is discussed. Many years of experience using the drug Licopid® in diseases associated with the mucous layers of the body, forming the mucosal immunity system, has shown high efficiency in therapy and prevention. On the example of clinical application showing the systemic use of the drug Licopid® in ophthalmology, the treatment of respiratory diseases, including acute respiratory children and adults infections, tuberculosis; diseases of the gastrointestinal and urogenital tracts, it has been demonstrated that Licopid® is effective in the immunoprophylaxis of various diseases, prevents relapse of acute respiratory infections, bacterial and herpetic children and adults infections, and is effective in the treatment and prevention of seasonal and allergic diseases. The study of the mechanism of Licopid® action, a wide range activity and the side effects absence are the basis for recommendations on the widespread use of GMDP in medical practice, immunotherapy and immunoprophylaxis.

Keywords:mucosal immunity; glucosaminyl muramyl dipeptide; innate immunity; immunotherapy; immunoprophylaxis

Funding. The study had no sponsor support.

Conflict of interests. Authors declare no conflict of interests.

For citation: Guryanova S.V, Khaitov R.M. Glucosaminylmuramyldipeptide - GMDP: effect on mucosal immunity (on the issue of immunotherapy and immunoprophylaxis). Immunologiya. 2020; 41 (2): 174-83. DOI: 10.33029/0206-4952-2020-41-2-174-183 (in Russian)

References

1. Khaitov R.M. Immunology. Textbook. 3rd ed. Moscow: GEOTAR-Media, 2016: 496 p. (in Russian)

2. Khaitov R.M., Garib F.Yu. Immunology. Atlas. Moscow: GEOTAR-Media, 2020: 416 p. (in Russian)

3. Khaitov R.M. Immunomodulators: myths and reality. Immunologiya. 2020; 41 (2) 00–00. (in Russian)

4. Khaitov R.M., Pinegin B.V., Pashchenkov M.V. Epithelial cells of the respiratory tract as equal participants of innate immunity and potential target for immunotropic drugs. Immunologiya. 2020; 41 (2): 00–00. (in Russian).

5. Bienenstock J., Befus D. Gut- and bronchus-associated lymphoid tissue. Am. J. Anat. 1984; 170 (3): 437–45.

6. Meshcheryakova E., Makarov E., Philpott D., Andronova T., Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminy N-acetylmuramyl peptides. Vaccine. 2007; 25: 4515–20.

7. Negroni A., Pierdomenico M., Cucchiara S., Stronati L. NOD2 and inflammation: current insights. J. Inflamm. Res. 2018; 11: 49–60.

8. Al Nabhani Z., Dietrich G., Hugot J.-P., Barreau F. NOD2: the intestinal gate keeper. PLoS Pathog. 2017; 13 (3): e1006177. DOI: 10.1371/ journal.ppat.1006177.

9. Okumura S., Yuki K., Kobayashi R., Okamura S., Ohmori K., Saito H., et al. Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells. Clin. Immunol. 2009; 130: 175–85. DOI: 10.1016/j.clim.2008.08.027.

10. Sidiq T., Yoshihama S., Downs I., Kobayashi K.S. Nod2: a critical regulator of ileal microbiota and Crohn’s disease. Front. Immunol. 2016; 7: 367.

11. Maychuk Yu.F. Ten years of experience with the use of the Likopid immunomodulator in the treatment of inflammatory eye diseases. Refraktsionnaya khirurgiya i oftal’mologiya. 2005; 5 (2): 52–7. (in Russian)

12. Maychuk Yu.F. Allergic conjunctivitis and allergic asthma. Diagnosis, clinic, treatment. Refraktsionnaya khirurgiya i oftal’mologiya. 2005; 5 (4): 24–30. (in Russian)

13. Maychuk Yu.F., Pozdnyakov V.I., Pozdnyakova V.V. Complex therapy of severe inflammatory eye diseases using immunomodulators and specific treatment agents. Moscow, 2010: 18 p. (in Russian)

14. Ivanova O.N., Sofroneeva O.L. Treatment of viral keratitis. Ural’skiy meditsinskiy zhurnal. 2019; 6 (174): 128–32. (in Russian)

15. Sizyakina L.P., Andreeva I.I., Petruchik S.V. Optimization of therapy for a patient with a genetic defect in antibody production. Vestnik Rossiyskogo universiteta druzhby narodov. Seriya: Meditsina. 2019; 23 (4): 405–11. DOI: 10.22363/2313-0245-2019-23-4-405-411. (in Russian)

16. Afanas’ev S.S., Aleshkin V.A., Voropaeva E.A., Afanas’ev M.S., Slobodenyuk V.V., Karaulov A.V. Microbiocenoses of open cavities and mucosal immunity.Effektivnaya farmakologiya. 2013; 27: 6–12. (in Russian)

17. Wade W.G. Detection and culture of novel oral Bacteria. In: N.S. Jakubovics, R.J. Palmer (eds). Oral Microbial Ecology – Current Research and New Perspectives. Norfolk: Caister Academic Press, 2013: 212 p.

18. Mysak J., Podzimek S., Sommerova P., Lyuya-Mi Y., Bartova J., Janatova T., Prochazkova J., Duskova J. Porphyromonas gingivalis: major periodontopathic pathogen overview. J. Immunol. Res. 2014; 2014: 4760688. URL: http://dx.doi.org/10.1155/2014/476068.

19. Ye C., Katagiri S., Miyasaka N., Kobayashi H., Khemwong T., Nagasawa T., Izumi Y. The periodontopathic bacteria in placenta, saliva and subgingival plaque of threatened preterm labor and preterm low birth weight cases: a longitudinal study in Japanese pregnant women. Clin. Oral Investig. 2020 Apr 24. DOI: 10.1007/s00784-020-03287-4.

20. Claudel J.P., Auffret N., Leccia M.T., Poli F., Corvec S., Dréno B. A potential new player in the physiopathology of acne? Dermatology. 2019; 235 (4): 287–94.

21. Hon K.L., Tsang Y.C., Pong N.H., Leung T.F., Ip M. Exploring Staphylococcus epidermidis in atopic eczema: friend or foe? Clin. Exp. Dermatol. 2016; 41 (6): 659–63. DOI: 10.1111/ced.12866.

22. Rabinovich O.F., Hanukhova L.M., Pinegin B.V. The effect of the immunomodulator of lycopid on the synthesis of cytokines and activation molecules of peripheral blood lymphocytes in patients with lichen planus. Stomatologiya. 2000: 79 (2): 69. (in Russian)

23. Petrova L.V., Il’ina L.V. Topical use of cyclosporin A in the treatment of various clinical forms of lichen planus. Vestnik dermatologii and venerologii. 2005; 2: 12–5. (in Russian)

24. Rabinovich O.F., Rabinovich I.M., Abramova E.S. The use of lycopide in the treatment of dysbiosis of the oral cavity. Stomatologiya. 2013; 92 (1): 40–2. (in Russian)

25. Guryanova S.V., Borisova O.Yu., Kolesnikova N.V., Lezhava N.L., Kozlov I.G., Gudima G.O. The effect of muramyl peptide on the microbial composition of the microflora of the oral cavity. Immunologiya. 2019; 40 (6): 34–40. DOI: 10.24411/0206-4952-2019-16005. (in Russian)

26. Balabolkin I.I., Kuznetsova N.I., Kuznetsova O.Yu. Changes during treatment with lycopide in the immune status of children with recurrent herpetic stomatitis, suffering from allergic diseases. Stomatologiya. 2004; 3: 4952. (in Russian)

27. Nesterova I.V., Kolesnikova N.V., Nedel’ko N.A. Method for immunocorrection of lycopide with local immunity disorders in patients with acute odontogenic periostitis. Stomatolog-praktik. 2006; 12 (148): 30–1. (in Russian)

28. Burney P., Jarvis D., Perez-Padilla R. The global burden of chronic respiratory disease in adults. Int. J. Tuberc. Lung Dis. 2015; 19 (1): 10–20.

29. Pinegin B.V., Pashchenkov M.V. Muramyl peptide immunostimulants in the treatment and prevention of infectious and inflammatory processes. Immunologiya. 2019; 3: 65–71. (in Russian)

30. Nesterova I.V., Kovaleva S.V., Kleshchenko E.I., Kolesnikova N.V., Chudilova G.A., Lomtatidze L.V., Shinkareva O.N., Malinovskaya V.V., Vyzhlova E.N. New approaches to conducting interferon and immunomodulating therapy in immunocompromised children with recurrent acute respiratory viral infections associated with herpesvirus infections. Lechashchiy vrach. 2014; 4: 107–11. (in Russian)

31. Stagnieva I.V., Simbirtsev A.S. The effectiveness of immunomodulating therapy in patients with rhinosinusitis. Meditsinskaya immunologiya. 2015; 17 (5): 423–30. (in Russian)

32. Filatova S.V., Pinegin B.V., Simonova A.V., Artem’ev M.E., Golubeva N.M. Clinical and immunological efficacy of Lycopid in the conservative treatment of patients with chronic tonsillitis and chronic sinusitis. Vestnik otorinolaringologii. 2001; 5: 26–8. (in Russian)

33. Luginova E.F. Methods of preventive treatment of children infected with drug-resistant strains of mycobacterium tuberculosis and with manifestations of immunobiological disorders. Yakutskiy meditsinskiy zhurnal. 2007; (1): 16–20. (in Russian)

34. Sukhov V.M., Gnezdilova E.V. On the feasibility of using Likopid in the treatment of tuberculosis infection. Terra Medica. 2003; 1: 27–9. (in Russian)

35. Andronova T.M. The use of the immunomodulator lycopid in the complex treatment of pulmonary tuberculosis. Problemy tuberkuleza. 2002; 3: 21–5. (in Russian)

36. Kisina T.E., Freidlin I.S., Petrova A.A. In vitro effect of an immunomodulator of lycopid on granulocytes of the peripheral blood of tuberculosis patients. Meditsinskiy akademicheskiy zhurnal. 2004; 4 (4): 29. (in Russian)

37. Svistunova A.S., Arshinova S.S., Klimova S.V., Simonova A.V., Mazurov D.V., Golubeva N.M., Andronova T.M. Clinical and immunological efficiency of immunomodulator licopide in pulmonary tuberculosis. Immunologiya. 2000; 21 (5): 59–62. (in Russian)

38. Yushchenko A.A. Comparative evaluation of the effect of leukinferon and lycopid on phagocytic microbicidal factors in experimental leprosy. In: Immunodiagnosis and Immunorehabilitation for Leprosy, Tuberculosis and Other Chronic Diseases. 1998: 96–7. (in Russian)

39. Litvinov V. I. The use of immunotropic lycopide in the treatment of tuberculosis. In: Current Problems of Allergology, Clinical Immunology and Immunopharmacology. 1998: 299. (in Russian)

40. Serkova N.A., Serkov I.L., Kulakov A.V. The use of a new domestic immunocommodator Likopid to reduce seasonal incidence. Immunology. 2000; 3: 62–3. (in Russian)

41. Kiryukhin A.V., Parfenova N.A., Maksimova T.A., Shenogina N.A., L’vov A.V., Chumakova M.M., Andronova T.M. Optimization of treatment for frequently and long-term ill children: immunocorrection with lycopid. Rossiyskiy pediatricheskiy zhurnal. 2001; 5: 27–9. (in Russian)

42. Mayorov R.V., Chereshneva M.V., Verzilin S.D., Chereshnev V.A. The effectiveness of the use of immunocorrective drugs for the prevention of respiratory infections and their complications in frequently ill children of primary school age. Meditsinskaya immunologiya. 2013; 15 (3): 255–62. (in Russian)

43. Chopyak V.V., Potemkina G.A. Comparative characteristics of the effectiveness of the treatment of patients with frequently recurring acute respiratory infections against the background of immunodeficiency disorders using the drug Likopid. Vrachebnoe delo. 2013; 2: 106–17. (in Russian)

44. Nikitushkin V.D., Demina G.R., Shleeva M.O., Guryanova S.V., Ruggiero A., Berisio R., Kaprelyants A.S. A product of RpfB and RipA joint enzymatic action promotes the resuscitation of dormant mycobacteria. FEBS J. 2015; 282 (13): 250011. DOI: 10.1111/febs.13292.

45. Guryanova S.V., Kozlov I.G., Meshcheryakova E.A., Alekseeva L.G., Andronova T.M. Glucosaminylmuramyl dipeptide normalizes the Th1 / Th2 balance in atopic bronchial asthma. Immunologiya. 2009; 5: 305–8. (in Russian)

46. Kozlov I.G., Guryanova S.V., Kolesnikova N.V., Andronova T.M. Muramyl peptides and other agonists of innate immunity receptors in the treatment of allergic diseases. Rossiyskiy allergologicheskiy zhurnal. 2015; 5: 59–67. (in Russian)

47. Kozlov I.G., Kolesnikova N.V., Voronina E.V., Guryanova S.V., Andronova T.M. Glucosaminylmuramyl dipeptide and other innate immunity receptor agonists in the pathogenetic treatment of allergic diseases. Allergologiya and immunologiya. 2013; 14 (4): 281–7. (in Russian)

48. Yagubyan R.S., Sizyakina L.P. the effectiveness of allergen-specific immunotherapy in patients with seasonal allergic rhinitis complicated by secondary immune deficiency syndrome. Zhurnal fundamental’noy meditsiny i biologii. 2012; 2: 55–8. (in Russian)

49. Baranova N.I., Molotilov B.A., Kostin E.M. Immunotherapy in patients with bronchial asthma and allergic rhinitis. Immunopatologiya, allergologiya, infectlogiya. 2008; (4): 32–8. (in Russian)

50. Weber V.R., Moroz B.T. Antiallergic drugs and immunomodulators. In: Clinical Pharmacology for Dentists. Sankt Petersburg: Chelovek, 2008.

51. Kevorkov N.N., Bakhmet’ev B.A., Chereshnev V.A. The effectiveness of complex immunotherapy for infectious-allergic bronchial asthma (BA). International Journal of Immunorehabilitation. 1997; 7: 105–7. (in Russian)

52. Konorev M.R. The use of an immunomodulator of Lycopid when conducting anti-Helicobacter therapy of the first choice. Immunopatologiya, allergologiya, infectlogiya. 2012; 1: 45–50. (in Russian)

53. Milyutina L.N., Golubev A.O. Experience with the use of Lycopid for the rehabilitation of post-infectious salmonella bacterial carriage in children. Rossiyskiy vestnik perinatologii i pediatrii. 2015, 4: 100–8. (in Russian)

54. Khaitov R.M., Pinegin B.V., Butakov A.A. Immunotherapy of infectious postoperative complications using a new glycopine immunostimulator. Immunologiya. 1994; 2: 47–50. (in Russian)

55. Karsonova M. I., Pinegin B.V., Khaitov R.M. Immunocorrective therapy for surgical infection. Annaly khirurgicheskoy gepatologii. 1999; 4 (1): 88–96. (in Russian)

56. Chernetsova L.F., Zotov P.B., Sabirov A.Kh. The use of Lycopida in the treatment of patients with advanced cancer of the gastrointestinal tract. Meditsinskaya panorama. 2003; 5: 44–5. (in Russian)

57. Makatsaria A.D. Efficacy and safety of glucosaminylmuramyl peptide in the treatment of diseases associated with human papillomavirus: a systematic review. Akusherstvo, ginekologiya i reproduktsiya. 2019; 13 (2): 132–54. (in Russian)

58. Ivanova, O.N., Argunova, E.F. Study of the characteristics of immunity in children with multiple papillomas. Yakutskiy meditsinskiy zhurnal. 2018; (3): 107–9. (in Russian)

59. Pinegin B.V., Minkin G.N. The effect of glucosaminylmuramyl dipeptide on the immune status and clinical condition of patients with cervical lesions of the human papilloma virus. Immunologiya. 1994; 3: 46–9. (in Russian)

60. Stolyarova U.V., Khvorostukhina NF. Comprehensive treatment of cervical papillomavirus infection. Izvestiya Samarskogo nauchnogo tsentra RAN. 2014; 16 (4): 1456–8. (in Russian)

61. Manukhin I.B., Minkina G.M., Vysotskiy M.M., Kharlova O.G. Comprehensive treatment of patients with local and common condylomatosis of the cervix. Voprosy ginekologii, akusherstva i perinatologii. 2005; 4 (4): 22–6. (in Russian)

62. Smirnova I.V. Prevention of purulent inflammatory diseases of the uterine appendages using the Likopid immunomodulator. Immunopatologiya, allergologiya, infectlogiya. 2004; 2: 25–8. (in Russian)

63. Pynzar’ M.A., Agikova L.A., Minkin G.N., Andronova T.N., Pinegin B.V. The clinical experience of the immunomodulator lycopid in patients with bacterial vaginosis. Immunologiya. 1998; 5: 63–4. (in Russian)

64. Chernetsova L.F., Boltovich A.V., Zorina L.I., Subach E.B. Lycopid and cycloferon in the complex treatment of chlamydial genital infections in women. Remedium. Privolzh’e. 2003; 6: 30–1. (in Russian)

65. Tikhomirov A.L., Khol’nov A.I. Immunological aspects and clinical significance of the use of Lycopid in the complex conservative treatment of patients with uterine myoma. Kachestvo zhizni. Meditsina. 2008; 2: 45–8. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»